SIC
PVLA

Samalin Investment Counsel’s Palvella Therapeutics PVLA Stock Holding History

Samalin Investment Counsel’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6
Closed -$1K – 527
2019
Q4 		$1K Buy
+6
New +$1.66K ﹤0.01% 540

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samalin Investment Counsel's PVLA Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Palvella Therapeutics (PVLA) in Q1 2020, closing a stake of 6 shares — an estimated $1K sold.

Samalin Investment Counsel first reported a position in PVLA in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 95 funds tracked by Wall St. Rank hold PVLA as of Q1 2020.

  • Samalin Investment Counsel reported no remaining Palvella Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 6 Palvella Therapeutics shares in Q1 2020, an estimated $1K.
  • Samalin Investment Counsel first reported a position in Palvella Therapeutics in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's Palvella Therapeutics position peaked at $1K in Q4 2019.
  • 95 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.